How cells rebuild heme in drug‑processing enzymes (cytochrome P450 and nNOS)
Heme Insertase machinery for cytochrome P450 NO synthase
This project looks at how cellular helper proteins restore the heme part of enzymes that process drugs and chemicals, which matters for how medications and toxins are handled in people.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11263678 on NIH RePORTER |
What this research studies
Researchers are using a lab system that mimics cell conditions to watch how chaperone proteins (Hsp90/Hsp70) and other factors like tubulin put heme back into damaged drug‑processing enzymes such as cytochrome P450 and neuronal nitric oxide synthase. They will use biochemical techniques and mass spectrometry with model enzymes (apo‑nNOS and CYP2E1) to identify and define the roles of Hsp70, tubulin, and any new protein partners in the proposed 'heme insertase' machinery. The team aims to map the stepwise process cells use to reconstitute heme so these enzymes can work again. Results are expected to clarify why some enzymes lose function during drug metabolism and how cells repair them.
Who could benefit from this research
Good fit: People who have problems with drug metabolism, drug‑induced liver injury, unusual sensitivity to medications, or conditions linked to CYP2E1 or nitric oxide signaling would be the most relevant future candidates for clinical follow‑up based on this work.
Not a fit: Patients whose health issues are unrelated to drug metabolism or nitric oxide pathways are unlikely to see direct benefit from this basic molecular research.
Why it matters
Potential benefit: If successful, this work could lead to better ways to protect or restore drug‑metabolizing enzymes and ultimately reduce adverse drug reactions or improve drug effectiveness.
How similar studies have performed: Prior laboratory work already showed Hsp90 helps reinsert heme and early data suggest CYP2E1 follows a similar Hsp90/Hsp70‑dependent process, but identifying the full set of protein partners is a new step.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Osawa, Yoichi — University of Michigan at Ann Arbor
- Study coordinator: Osawa, Yoichi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.